Sign in

    Shinichiro Ueda

    Research Analyst at Goldman Sachs

    Shinichiro Ueda is an Equity Analyst at Goldman Sachs specializing in the coverage of the Japanese pharmaceutical sector, with recent direct engagement in research on Takeda Pharmaceutical Co Ltd. He has contributed to earnings call research and questions, reflecting active involvement with major industry players, though public performance metrics such as TipRanks rankings, average returns, or formal analyst ratings are not available. Ueda's career at Goldman Sachs includes public-facing research participation as of 2024, but specific details regarding previous employers or the timeline of his professional advancement remain undisclosed. Currently, there is no verifiable information about securities licenses, FINRA registration, or other professional certifications attributed to Shinichiro Ueda.

    Shinichiro Ueda's questions to TAKEDA PHARMACEUTICAL CO (TAK) leadership

    Shinichiro Ueda's questions to TAKEDA PHARMACEUTICAL CO (TAK) leadership • Q1 2025

    Question

    Shinichiro Ueda from Goldman Sachs asked about Takeda's launch preparations for oviporexant, specifically regarding the commercial team structure and the use of digital technologies to improve patient diagnosis for narcolepsy type 1.

    Answer

    U.S. Business Unit President Julie Kim confirmed that Takeda is actively preparing for the launch, with medical teams already educating in the field. She highlighted a focus on using multiple digital avenues to support and unlock bottlenecks in diagnosis, particularly through sleep centers, with more details to be shared closer to launch.

    Ask Fintool Equity Research AI